Aqtual
Advancing Precision Medicine Products in the Costliest Disease Areas
Mission
Aqtual’s mission is to revolutionize chronic disease and oncology management by bridging the translational gap between groundbreaking research and practical healthcare solutions. Through proprietary biochemistry, novel technology, and advanced data science, we are building a comprehensive catalog of disease-specific clinical features and developing highly accurate blood tests for disease detection, monitoring, and patient stratification across chronic inflammatory conditions and oncology.
Technology
In a major breakthrough, Aqtual discovered a way to measure epigenetics, gene regulation, and transcriptomics solely from analyzing cell-free DNA in a single blood draw.
By capturing circulating chromatin, cell-free DNA fragments that are largely inaccessible through standard lab methods, we are developing a novel catalog of tissue-, disease- and drug-specific targets in multiple therapeutic areas, including:
- Inflammatory conditions
- Oncology
- Immunology
- Cardiovascular diseases
- Metabolic diseases
- Neurological conditions
Beyond its tests, Aqtual is developing a new roadmap for drug development
- 200,000+ promoters
- 400,000+ enhancers
- 50,000+ insulators
- 20,000+ silencers
- 1M+ transcription factor binding sites
How it works:
- Blood draw
- Proprietary cell-free DNA capture
- Quantification
- Signal processing
- Validated catalog of clinically actionable signatures
Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic autoimmune and inflammatory disease. Patients can be on expensive therapeutics for years and often fail to respond to a prescribed treatment; in which case the guidelines recommend switching therapy.
Our initial focus is developing a groundbreaking blood test to guide therapy management for RA patients.
In a recent pilot study, we achieved positive clinical results by identifying biomarkers associated with treatment response in RA therapies.
We have initiated a prospective clinical study to enroll a diverse RA patient population undergoing therapy change. This study aims to provide performance measures of our test in a real-world setting and develop a classifier we will validate in larger studies.
Contacts
Have questions or need more information? Considering joining our team? We welcome any questions or inquiries you may have. Reach out to us by filling the following form or email us at media@aqtual.com